Olema Pharmaceuticals' stock plummets 41% after Roche trial data is announced

LootboxPhobia · 2026-03-09T22:46:16+00:00

Olema Pharmaceuticals stock price dropped 41% due to poor trial results for Roche's breast cancer therapy. Roche's study failed to show significant improvement, leading to a decline in its stock price as well. Olema continues to advance the development of palazestrant, and analysts believe the trial results may present a market opportunity for it, which investors can view as a buying opportunity.

LootboxPhobia

2026-03-09 22:46:16

Abstract generation in progress

Investing.com – Olema Pharmaceuticals (NASDAQ:OLMA) stock fell 41% on Monday after disappointing late-stage trial results for a breast cancer therapy announced by peer developer Roche.

Roche announced that its giredestrant combined with palbociclib did not meet the primary endpoint in the Phase 3 persevERA study, which was progression-free survival, showing no statistically significant improvement. Roche’s stock dropped as much as 7.5%, the largest decline in over 11 months.

Olema is advancing its experimental therapy, palazestrant, in multiple Phase 3 breast cancer trials. The company’s first-line metastatic breast cancer OPERA-02 study is not expected to report topline results until 2028.

Roche reported some numerical improvements in the trial but did not achieve statistical significance. Stifel analyst noted that while this result is not ideal for Olema’s stock in the short term, the numerical improvements suggest that palazestrant’s potent antagonistic effects and pharmacokinetic properties still have the potential to be meaningful differentiators in first-line metastatic treatment.

The company commented that investors who believe in palazestrant’s best-in-class potential might see today’s sell-off as a buying opportunity, as Roche’s setback leaves room for palazestrant to become the first major driver in the first-line metastatic breast cancer field.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.